Combined marker for predicting liver cancer risk of male hepatitis B virus infected person and application thereof

Abstract

The invention discloses a combined marker for predicting the liver cancer risk of male hepatitis B virus infected persons and application of the combined marker. The combined marker comprises at least one of gamma-glutamyl transpeptidase, platelets, leukocytes, albumin and liver cirrhosis indexes, alpha fetoprotein and abnormal prothrombin. According to the invention, early warning can be realized 1-2 years before HCC nodules appear in iconography in liver cancer high-risk patients, and the early liver cancer (lt; and meanwhile, the worry of many low-risk asymptomatic HBsAg positive persons is relieved, and the HCC monitoring and screening frequency is reduced. And 4) economic and effective layered screening can be realized from the aspect of public health.

Description

technical field [0001] The invention belongs to the field of biomedical technology, and relates to a combined marker for predicting the risk of liver cancer in male hepatitis B virus infected patients and its application. Background technique [0002] Hepatocellular Carcinoma (HCC) is the main pathological type of primary liver cancer. Through regular monitoring of HCC high-risk groups, early HCC patients can be found and treated appropriately to improve prognosis. Patients with liver cirrhosis are recognized as a high-risk group for HCC. International professional academic institutions recommend regular monitoring of HCC in patients with liver cirrhosis, usually every 3-6 months for serum alpha-fetoprotein (AFP) Joint abdominal B-ultrasound examination. A variety of chronic liver diseases can lead to liver cirrhosis, including chronic hepatitis B virus (Hepatitis B Virus, HBV) infection, etc. Chronic HBV infection mainly refers to those with positive blood hepatitis B surf...

AI Technical Summary

Problems solved by technology

However, the following main problems have been found in practical work: 1) HCC monitoring twice a year has caused great anxiety for many asymptomatic HBsAg-positive people and increased the workload of follow-up; 2) HCC monitoring is carried out in all HBsAg-positive people and screening, and did not prove that this technical solution has the effect of improving the long-term survival of the population; 3) The cost-effectiveness of HCC monitoring and screening in all HBsAg-positive populations is poor

These models have the following problems: 1) the effect in the asymptomatic HBsAg-positive population is unknown; 2) there are significant gender differences in the relevant clinical test values ​​in the normal population, but the above models adopt uniform standards and values; 3) Transient elastography requires special instruments, is expensive and is easily affected by subjective interpretation; 4) It is difficult to reflect the occurrence of HCC in the recent 1-2 years, which leads to anxiety in high-risk groups

Images